Clinical trials: Endothelial Degeneration
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Exudative Age-related Macular Degeneration
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
The purpose of this study is to examine the plasma concentration of vascular endothelial growth factor (VEGF) after standard treatment with one of the newest growth factor inhibitors, aflibercept (Eylea).
- Trial name
- Eylea-2014 (NCT02125864)
- Testing
- intravitreal injection
- Volunteers
- 16 people
- Sponsor
- Oslo University Hospital
Age-related Macular Degeneration
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
This is a pilot, prospective, interventional, case-control study investigating aqueous levels of vascular endothelial growth factor (VEGF) in eyes with AMD-related neovascularization treated with intravitreal bevacizumab at the…
- Trial name
- NCT01350323
- Testing
- Aqueous sample
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- University of Molise
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Arterial Disease, Frail Elderly Syndrome
Relationship Between Digital Vascular Function Measured by EndoPAT® in elderlY Patients and Arterial Stiffness
Due to the aging of populations worldwide, we observe an increase of age-related diseases and loss of autonomy with consequent personal, social, medical and economic implications.
- Conditions
- Arterial Disease, Frail Elderly Syndrome, Stiffness, Vascular, Endothelial Degeneration
- Trial name
- ENDY (NCT04651894)
- Testing
- reactive hyperaemia index measurement
- Where
- France
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Neovascular Age-related Macular Degeneration (nAMD)
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
- Trial name
- NOVA-1 (NCT05769153)
- Testing
- AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant
- Where
- 42 sites in United States
- Volunteers
- 139 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.
- Trial name
- NCT05678517
- Testing
- Anti-VEGF
- Where
- 2 sites in Hungary
- Volunteers
- 47 people
- Sponsor
- Semmelweis University
Retinal Vasculitis
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
- Trial name
- NCT07105228
- Testing
- aflibercept 2mg
- Where
- United States
- Volunteers
- 290,000 people
- Sponsor
- Regeneron Pharmaceuticals
Choroidal NeoVascularization, Age-Related Macular Degeneration
Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which…
- Trial name
- NCT00813514
- Testing
- VEGF genotyping
- Where
- Austria
- Sponsor
- Medical University of Vienna
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Low Vision, Neovascular Age-related Macular Degeneration
Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) Therapy
The purpose of this research is to collect preliminary data in preparation for conducting a randomized clinical trial to determine the relative effectiveness of vision rehabilitation in improving overall visual ability (primary…
- Trial name
- TRAVIT (NCT03065907)
- Testing
- Vision rehabilitation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Neovascular Age-related Macular Degeneration
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).
- Trial name
- Z-AMD (NCT04304755)
- Testing
- Zoledronic Acid 5 MG in 5 ML Injection
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
AMD, nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ASCENT (NCT05407636)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Where
- 181 sites in United States, Canada and 8 more
- Volunteers
- 735 people
- Sponsor
- AbbVie
Fuch's Endothelial Dystrophy, Pseudophakic Bullous Keratopathy
Comparison of Corneal Grafts Cultured in Serum-free Versus Corneal Grafts Cultured in Serum Supplemented Culture Media
The goal of this clinical trial is to compare the quality of corneal grafts cultured in a serum-free culture medium with a defined composition versus corneal grafts cultured in a standard serum supplemented culture medium…
- Trial name
- SFM (NCT00623584)
- Testing
- Corneal transplantation
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Klinikum Chemnitz gGmbH
Macular Edema Due to Type 2 Diabetes Mellitus
Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema
The goal of this clinical trial is to clarify the efficacy of anti-vascular endothelial growth factor (anti-VEGF) drugs combined with subthreshold micropulse laser (SML) therapy on retinal function and anatomical recovery in…
- Trial name
- VEGF (NCT05759884)
- Testing
- Anti-VEGF, subthreshold micropulse laser
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetic Macular Edema
Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Currently, two similar medications are available for injection into the eye to treat a variety of eye diseases. These medications are called ranibizumab (Lucentis) and bevacizumab (Avastin).
- Trial name
- NCT01661946
- Testing
- Bevacizumab, Ranibizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Queen's University
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
- Trial name
- NCT06116890
- Testing
- KHK4951, Aflibercept Injection
- Where
- 84 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Kyowa Kirin Co., Ltd.